Loncar Cancer Immunotherapy ETF (CNCR) ist ein börsennotiertes Unternehmen im Finanzdienstleistungen Sektor, tätig in der Asset Management Branche.
CNCR hat IPO-Datum 2015-10-14, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $7.04M.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
